Literature DB >> 22886543

Evidence of time-dependent prognostic factors predicting early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients.

Hervé Ghesquières1, Youenn Drouet, Marie Pierre Sunyach, Catherine Sebban, Catherine Chassagne-Clement, Emmanuel Jouanneau, Jérome Honnorat, Pierre Biron, Jean Yves Blay.   

Abstract

Long-term primary CNS lymphoma (PCNSL) survivors could have multiple adverse prognostic factors at diagnosis such as age, performance status (PS), site of the tumour (deep vs superficial), lactate dehydrogenase (LDH) level and CSF protein level. Whether these five prognostic factors integrated in the International Extranodal Lymphoma Study Group (IELSG) score have a time-dependent effect is questionable. Among 132 PCNSL patients treated at our institution between 1984 and 2006, 91 available patients for IELSG score were evaluated by time-segmented analysis. Of the 91 patients, 21% had 0-1, 59% had 2-3 and 20% had 4-5 adverse IELSG prognostic scores. With a median follow-up of 102 months, the median overall survival (OS) of the 91 patients with the five prognostic factors of IELSG score was 33 months (95% CI, 17 to 55) compared with 14 months (95% CI, 3 to 23) for the remaining 41 patients whose CSF protein level was lacking in the IELSG score. These 41 patients who did not have lumbar puncture presented a poorer PS at diagnosis and a lower treatment response rate. While confirming the prognostic value of the IELSG score, we observed a time-dependent effect of age, PS and tumour site; all three lost their prognostic value after 6 months from diagnosis, while LDH remained a constant predictor of OS. No prognostic impact of CSF protein level was reported. Patients with older age, poor PS and deep brain involvement are at risk of death during the first months after diagnosis but could have a favourable long-term outcome after the treatment period. New prognostic factors predicting long-term outcome remain to be determined.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22886543     DOI: 10.1002/hon.2021

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  6 in total

1.  Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases.

Authors:  Jing Liu; Xue-Fei Sun; Jun Qian; Xue-Yan Bai; Hong Zhu; Q U Cui; Xiao-Yan Li; Yue-Dan Chen; Ya-Ming Wang; Yuan-Bo Liu
Journal:  Mol Clin Oncol       Date:  2015-05-12

2.  Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?

Authors:  Torstein R Meling; Anna Latysheva; Michele Da Broi; Guro Jahr; Harald Holte; Klaus Beiske; Kyrre Eeg Emblem
Journal:  Neuroradiology       Date:  2018-05-27       Impact factor: 2.804

3.  Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.

Authors:  Emeline Tabouret; Caroline Houillier; Nadine Martin-Duverneuil; Marie Blonski; Carole Soussain; Herve Ghesquières; Roch Houot; Delphine Larrieu; Pierre Soubeyran; Remy Gressin; Emmanuel Gyan; Olivier Chinot; Luc Taillandier; Sylvain Choquet; Agusti Alentorn; Delphine Leclercq; Antonio Omuro; Marie-Laure Tanguy; Khe Hoang-Xuan
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

4.  Risk Prediction for Early Mortality in Patients with Newly Diagnosed Primary CNS Lymphoma.

Authors:  Chia-Hsin Lin; Ching-Fen Yang; Huai-Che Yang; Li-Yu Fay; Chiu-Mei Yeh; Ai-Seon Kuan; Hao-Yuan Wang; Jyh-Pyng Gau; Liang-Tsai Hsiao; Tzeon-Jye Chiou; Po-Min Chen; Yao-Chung Liu; Po-Shen Ko; Jin-Hwang Liu; Chia-Jen Liu
Journal:  J Cancer       Date:  2019-07-05       Impact factor: 4.207

5.  Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study.

Authors:  Yoko Nakasu; Koichi Mitsuya; Nakamasa Hayashi; Ikue Okamura; Keita Mori; Terukazu Enami; Raine Tatara; Satoshi Nakasu; Takashi Ikeda
Journal:  Springerplus       Date:  2016-03-10

6.  Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma.

Authors:  Guro Jahr; Michele Da Broi; Harald Holte; Klaus Beiske; Torstein R Meling
Journal:  Brain Behav       Date:  2018-02-05       Impact factor: 2.708

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.